首页> 外文期刊>Infection and Drug Resistance >Synergism of cationic antimicrobial peptide WLBU2 with antibacterial agents against biofilms of multi-drug resistant Acinetobacter baumannii and Klebsiella pneumoniae
【24h】

Synergism of cationic antimicrobial peptide WLBU2 with antibacterial agents against biofilms of multi-drug resistant Acinetobacter baumannii and Klebsiella pneumoniae

机译:阳离子抗菌肽WLBU2与抗菌剂对多重耐药性鲍曼不动杆菌和肺炎克雷伯菌的生物膜的协同作用

获取原文
           

摘要

Purpose: The activity of the cationic antimicrobial peptide WLBU2 was evaluated against planktonic cells and biofilms of multi-drug resistant (MDR) Acinetobacter baumannii and Klebsiella pneumoniae , alone and in combination with classical antimicrobial agents. Methods: Control American Type Culture Collection (ATCC) strains and MDR clinical isolates of A. baumannii and K. pneumoniae were utilized. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of WLBU2 alone and in combination with antimicrobials were determined by classical methods. The Calgary biofilm device was used to determine the minimum biofilm eradication concentration (MBEC). The MTT assay was used to determine the cytotoxicity of agents on eukaryotic cells. The electrophoretic mobility shift assay was used to evaluate the ability of WLBU2 to bind bacterial DNA. Results: The WLBU2 MIC and MBC values were identical indicating bactericidal activity. The MIC/MBC values ranged from 1.5625 to 12.5 μM. At these concentrations, Vero cells and human skin fibroblasts were viable. The MBEC of WLBU2 ranged from 25 to 200 μM. A significant loss of eukaryotic cell viability was observed at the MBEC range. The combination of sub-inhibitory concentrations of WLBU2 with amoxicillin-clavulanate or ciprofloxacin for K. pneumoniae , and with tobramycin or imipenem for A. baumannii , demonstrated synergism, leading to a significant decrease in MIC and MBEC values for some isolates and ATCC strains. However, all combinations were associated with considerable loss in eukaryotic cells’ viability. WLBU2 did not demonstrate the ability to bind bacterial plasmid DNA. Conclusion: WLBU2 in combination with antimicrobials holds promise in eradication of MDR pathogens.
机译:目的:单独和与经典抗微生物剂联合使用时,评估了阳离子抗微生物肽WLBU2对抗浮游生物细胞和多重耐药(MDR)鲍曼不动杆菌和肺炎克雷伯菌的生物膜的活性。方法:采用美国典型培养物保藏中心(ATCC)菌株和鲍曼不动杆菌和肺炎克雷伯氏菌的MDR临床分离株。 WLBU2单独和与抗菌素联合使用时的最小抑菌浓度(MIC)和最小杀菌浓度(MBC)通过经典方法确定。卡尔加里生物膜设备用于确定最小生物膜根除浓度(MBEC)。使用MTT测定法确定试剂对真核细胞的细胞毒性。电泳迁移率变动分析用于评估WLBU2结合细菌DNA的能力。结果:WLBU2 MIC和MBC值相同,表明具有杀菌活性。 MIC / MBC值范围为1.5625至12.5μM。在这些浓度下,Vero细胞和人皮肤成纤维细胞是可行的。 WLBU2的MBEC范围为25至200μM。在MBEC范围内观察到真核细胞活力的显着损失。亚抑制浓度的WLBU2与阿莫西林-克拉维酸盐或环丙沙星对肺炎克雷伯菌的结合,与妥布霉素或亚胺培南对鲍曼不动杆菌的结合表现出协同作用,导致某些分离株和ATCC菌株的MIC和MBEC值显着降低。但是,所有这些组合都与真核细胞活力的大量丧失有关。 WLBU2没有展示结合细菌质粒DNA的能力。结论:WLBU2结合抗菌药物有望根除MDR病原体。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号